NCT03875261 (EdomTHC) is a Phase 2 clinical trial of Cannabinoid treatment in Endometriosis, sponsored by David Garcia Cinca.

Who is sponsoring NCT03875261?

NCT03875261 is sponsored by David Garcia Cinca.

What drugs are being tested in NCT03875261?

Interventions in NCT03875261: Cannabinoid treatment.

What condition does NCT03875261 study?

NCT03875261 studies Endometriosis.

Is NCT03875261 still recruiting?

NCT03875261 is currently status unknown. Last updated 14 March 2019.

Last reviewed 2019-03-14 · How we verify

NCT03875261: EdomTHC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis

Status unknown Phase 2 Last updated 14 March 2019

What this trial tests

Phase 2 trial testing Cannabinoid treatment in Endometriosis in 10 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
15 July 2019

15 July 2019

Quick facts

Lead sponsor	David Garcia Cinca
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 April 2019
Primary completion	15 July 2019
Estimated completion	15 July 2019
Sites	1 location across Spain

Drugs / interventions tested

Cannabinoid treatment — full drug profile →

Conditions studied

Endometriosis — all drugs for Endometriosis →

Sponsor

David Garcia Cinca — full company profile →

Who can join

Adults 18 to 40, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the treatment of the symptoms of deep endometriosis with a cannabinoid derivate.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.
Maia J, Fonseca BM, Teixeira N, Correia-da-Silva G. · · 2020 · cited 73× · PMID 32347309 · DOI 10.1093/humupd/dmaa005
Disease-modifying effects of natural Δ9-tetrahydrocannabinol in endometriosis-associated pain.
Escudero-Lara A, Argerich J, Cabañero D, Maldonado R. · · 2020 · cited 30× · PMID 31931958 · DOI 10.7554/elife.50356
Endometriosis and pain in the adolescent- striking early to limit suffering: A narrative review.
Sieberg CB, Lunde CE, Borsook D. · · 2020 · cited 29× · PMID 31862211 · DOI 10.1016/j.neubiorev.2019.12.004
A Scoping Systematic Review of Cannabis Use in Endometriosis.
McLaren K, Erridge S, Sodergren MH. · · 2026 · PMID 41367152 · DOI 10.1111/ajo.70081
Is it the Ideal Time to Start Prescribing Cannabis Derivatives to Treat Endometriosis-associated Pain?
Poli-Neto OB, Hallak JEC, Hallak JEC, Rosa-E-Silva JC, et al · · 2022 · PMID 35697067 · DOI 10.1055/s-0042-1749430

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting

Other David Garcia Cinca trials

Trials by the same sponsor.

NCT04301375 — Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 · Phase 2 · not yet recruiting
NCT03955328 — Progression of Damage in Ulcerative Colitis · NA · unknown
NCT03609099 — Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clin · Phase 4 · unknown
NCT02872155 — Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephr · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03875261 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Garcia Cinca
Last refreshed: 14 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03875261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing